Expert Interview
A second discussion on EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Ticker(s): EYPT, FDMT, RHHBY, REGNInstitution: Self-Employed
- Board-certified ophthalmologist and award-winning retinal specialist, Medical Director for the Macular Degeneration Association (MDA) and Founder & CEO of Mali Enterprises
- manages 2,000 patients with GA and utilizes the most advanced surgical techniques and technology in the world to deliver the highest quality retinal surgery for his patients
- Interested in new treatments for wet macular degeneration, diabetic retinopathy, and uveitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
